CN1679639A - Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract - Google Patents
Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract Download PDFInfo
- Publication number
- CN1679639A CN1679639A CNA2005100106168A CN200510010616A CN1679639A CN 1679639 A CN1679639 A CN 1679639A CN A2005100106168 A CNA2005100106168 A CN A2005100106168A CN 200510010616 A CN200510010616 A CN 200510010616A CN 1679639 A CN1679639 A CN 1679639A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- blood
- chinese medicine
- radix notoginseng
- blood circulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of capsule for promoting blood circulation, and treating more than 18 diseases including coronary heart disease, angina pectoris, acute myocardial infarction, cerebral thrombus, cerebral infarction, hyperlipemia, etc is prepared from notoginsen and leech-through extracting.
Description
Technical field
The present invention relates to a kind of is the oral medication-blood circulation and channel invigorating soft capsule of feedstock production with invigorate blood circulation Chinese medicine Radix Notoginseng and Hirudo extract of plant.
Background technology
1, Chinese patent application 98106597.X discloses a kind of " XUESAITONG RUANJIAONANG and preparation technology thereof ", this product is made of medicinal liquid and softgel shell two large divisions, it is characterized in that medicinal liquid by weight every contain 40～250 milligrams of Radix Notoginseng total arasaponins (glycosides) and contain solvent and stabilizing agent, contain 10 parts in gelatin in the softgel shell, glycerol 3.25～3.35 portions of (weight ratio) and antiseptic.
Chinese patent application numbers 99114718.9 discloses a kind of " Radix Notoginseng total arasaponins (glycoside) soft capsule and preparation method thereof ", this product is made of medicinal liquid and softgel shell two large divisions, medicinal liquid in every soft capsule includes 10～100 milligrams of Radix Notoginseng total arasaponinss (glycoside), is that 2～10 times high viscosity edible vegetable oil of Radix Notoginseng total arasaponins (glycoside) or alcohol are as adjuvant with weight; Include 1 part in gelatin in the softgel shell, 0.35～0.65 part of glycerol and moisture.
Radix Notoginseng total arasaponins (glycoside) is the extract of medical material Radix Notoginseng, is a kind of mixture, and the market is on sale, it is made the oral type pharmaceutical formulation as main medicinal ingredient and other adjuvant in the prior art.But existing with Radix Notoginseng total arasaponins (glycoside) and Hirudo extract be the oral medication of feedstock production a kind of be that the oral medication-blood circulation and channel invigorating soft capsule of feedstock production does not appear in the newspapers with invigorate blood circulation Chinese medicine Radix Notoginseng and Hirudo extract of plant.
2, cardiovascular and cerebrovascular disease is commonly encountered diseases, the frequently-occurring disease that threatens human health, and mortality rate rises to human three one of the reasons of dying of illness greatly year by year.At present, the method and the medicine of integrative therapy cardiovascular and cerebrovascular disease are a lot, Chinese medicine particularly, and because of the curative effect height, toxic and side effects is little, has original advantage.But Chinese medicine ubiquity dosage form falls behind, dose is big, onset waits defective slowly.Develop new product of Chinese medicine efficient, quick-acting, that dose is little and become the key that Chinese medicine goes to the world.
Soft capsule has obtained increasing application clinically as a kind of new formulation, and its made pharmaceutical preparation is not only rapid-action, the curative effect height, and stability is better, taking convenience, and exquisite appearance, the patient is easy to characteristics such as acceptance, is worthy to be popularized very much.Our work is exactly to have utilized this advantage of soft capsule, invents a kind of blood circulation and channel invigorating soft capsule, is beneficial to bring into play better the curative effect of Radix Notoginseng total arasaponins and Hirudo, serves clinical.
Summary of the invention
The object of the present invention is to provide two kinds to be that having of feedstock production absorbs oral medication fast, rapid-action, the bioavailability advantages of higher with Radix Notoginseng total arasaponins (glycoside) and Hirudo extract.
The present invention is made by following raw materials in weight:
Radix Notoginseng total arasaponins (glycoside) 0.025g-0.1g, Hirudo extract 0.25g-0.5g.
This product raw material is the extract of Radix Notoginseng total arasaponins and Hirudo, Radix Notoginseng total arasaponins is the effective ingredient that extracts from the rare medicinal herbs Radix Notoginseng, pharmacological research shows: it has blood vessel dilating, increase the heart and brain blood flow, reduce myocardial oxygen consumption, bring high blood pressure down, suppress platelet aggregation, reduce blood viscosity etc., so obtained a large amount of application clinically, positive effect has been played in the treatment of cerebrovascular disease, and for the clinical efficacy of better performance Radix Notoginseng total glycosides, medical worker has carried out a large amount of research to its preparation.At present, be that the medicine that primary raw material is made has XUESAITONG PIAN with the Radix Notoginseng total arasaponins, granule, capsule and injection.Hirudo is China's Chinese medicine, just on the books in the Shennong's Herbal before in 1 thousand 8 hundred, the traditional Chinese medical science thinks and the curative effect that it has removing blood stasis, removing blood stasis, stimulates the menstrual flow is mainly used in treatment tumor disease, mass in the abdomen, blood stasis, amenorrhea and traumatic injury that west hirudin also commonly used is sucked blood to treat some disease.Extracted the various active composition from Hirudo and salivary gland thereof, hirudin is maximum a kind of composition of the most remarkable wherein active and research, the small protein that it is made up of 65-66 aminoacid (polypeptide).Hirudin has extremely strong inhibitory action to thrombin, the natural special inhibitor of the strongest thrombin that is up to now to be found.Animal experiment and clinical research show, hirudin can efficient anticoagulation/antithrombotic forms and prevents further blood stasis phenomenons such as the thrombin activation of catalyzed by thrombin and platelet response, in addition, it can also the inductive fibroblasts proliferation of Trombin inhibiting and thrombin to the stimulation of endotheliocyte.Compare with heparin, not only consumption is few for it, can not cause bleeding, and does not also rely on the endogenous cofactor; And heparin is by there being the danger that causes bleeding, and antithrombase often reduces in the pathogenic process of disseminated inravascular coagulation, and this will limit the curative effect of heparin, adopts hirudin to have effect preferably.
The present invention has following advantage and effect:
Compare with the swallow preparation of administration of tradition, the blood circulation and channel invigorating soft capsule has fast, rapid-action, the bioavailability advantages of higher of absorption, is quick-acting, efficient modern medicines preparation.Coronary circulation-promoting pain-relieving of the present invention is used for removing blood stasis, and promoting blood circulation to remove blood stasis stimulates the menstrual flow, coronary circulation-promoting pain-relieving; Coronary heart disease, angina pectoris, acute myocardial infarction; Ischemia apoplexy is as cerebral thrombosis, cerebral infarction and sequela thereof, high blood viscosity, hyperlipidemia, chronic hypertension; Tremulous pulse medicated porridge sclerosis, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained, fat person etc. belong to expectorant stasis of blood cohesion person, can be used for the lump in the abdomen mass in the abdomen, peripheral angiopathy from fall and heat.
Clinical trial of the present invention:
The 150 row clinical verifications of blood circulation and channel invigorating soft capsule treatment hyperlipidemia are observed
Table 1
| ??? Before the treatment | ??? After the treatment | ??? Significance test | |
| Mean ± standard deviation | Mean ± standard deviation | ????C??????P | |
| Cholesterol | ????207.6±41.7 | ????190.5±35.5 | ????5.968＜0.01 |
| Triglyceride | ????201.3±82.0 | ????146.5±54.5 | ????8.796＜0.01 |
The blood circulation and channel invigorating soft capsule can make the interior 6-ketone-prostaglandin of patient's body of hyperlipidemia, and both ratios of thromboxane are kept normally, and the blood vessel wall lipidosis reduces, and illustrates that the blood circulation and channel invigorating soft capsule has certain antianginal and effect for reducing fat.Show that the blood circulation and channel invigorating soft capsule is to prevent and treat the atherosclerosis and the multiple heart, brain, a kind of new product of renal vascular.
Blood circulation and channel invigorating soft capsule and the 48 row clinical verifications of XUESAITONG RUANJIAONANG double-blind treatment coronary heart disease are observed
Table 2 is taken medicine and the influence of XUESAITONG RUANJIAONANG to triglyceride
| Group | The example number | (mg%) mean ± standard deviation before the treatment | Treatment back (mg%) mean ± standard deviation | |
| The A group | ????24 | ????170.56±51.63 | ????112.5±47.57 | ????＜0.01 |
| The B group | ????24 | ????139.92±52.75 | ????148.67±67.74 | ????＞0.05 |
Table 3 take medicine with XUESAITONG RUANJIAONANG to anginal influence
| Group | The example number | Produce effects | Take a turn for the better | Invalid | Total effective rate |
| The A group | ??24 | ???18(75％) | ??6(25％) | ???0 | ??100％ |
| The B group | ??24 | ???5(20.83％) | ??7(29.17％) | ???12(50％) | ??50％ |
The table 4 blood circulation and channel invigorating soft capsule treatment back prothrombing time dynamic observes
| Prothrombing time＜12 12-＞13-＞14-＞15-＞16-＞17-＞18-＞19-adds up to several 00386421 100 % 12.5 87.5 24 of example |
Illustrate from top table 1-4:
1, with the patient of blood circulation and channel invigorating soft capsule treatment, blood fat generally descends, and triglyceride difference is more remarkable.
2, use in 24 examples of blood circulation and channel invigorating soft capsule treatment, produce effects 18 examples, 6 examples that take a turn for the better, total effective rate 100% is compared with XUESAITONG RUANJIAONANG, and P＜0.01 differs highly significant, illustrates that also this new drug has curative effect preferably to the coronary dilating pain relieving of angina pectoris.
3, take the blood circulation and channel invigorating soft capsule after one month, prothrombing time lengthening, but none example surpasses twice, most for not seeing side effect such as subcutaneous hemorrhage in the medium prolongation process.
Blood circulation and channel invigorating soft capsule clinical observation on the therapeutic effect
| Patient's sum (example) | Produce effects | Effectively | Total effective rate | |
| Chest pain | ????16 | ????5 | ????8 | ????81.3％ |
| Uncomfortable in chest | ????26 | ????9 | ????13 | ????84.6％ |
| Numb limbs and tense tendons | ????6 | ????2 | ????2 | ????66.7％ |
| Triglyceride | ????23 | ????9 | ????8 | ????74％ |
| Cholesterol | ????20 | ????5 | ????5 | ????50％ |
| ??APCA/APCB | ????15 | ????6 | ????4 | ????67％ |
| Whole blood viscosity | ????21 | ????8 | ????0 | ????38％ |
| Electrocardiographic abnormality | ????10 | ????2 | ????4 | ????60％ |
| Accumulative total | ????118 | ????46 | ????42 | ????74.6％ |
The specific embodiment
Embodiment
1, gets 0.025g Radix Notoginseng total arasaponins (glycoside) and 0.25g Hirudo extract, make oral capsule pharmaceutical preparation with prior art;
2, get 0.025g Radix Notoginseng total arasaponins (glycoside) and 0.5g Hirudo extract, make oral capsule pharmaceutical preparation with prior art;
3, get 0.05g Radix Notoginseng total arasaponins (glycoside) and 0.5g Hirudo extract, make oral capsule pharmaceutical preparation with prior art;
4, get 0.1g Radix Notoginseng total arasaponins (glycoside) and 0.5g Hirudo extract, make oral capsule pharmaceutical preparation with prior art.
Claims (1)
1, a kind of is the oral soft capsule pharmaceutical preparation of feedstock production with invigorate blood circulation Chinese crude drug Radix Notoginseng and Hirudo extract.It is characterized in that being prepared from by 0.025g-0.1g Radix Notoginseng total arasaponins (glycoside) and 0.25g-0.5g Hirudo extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100106168A CN1679639A (en) | 2005-01-25 | 2005-01-25 | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100106168A CN1679639A (en) | 2005-01-25 | 2005-01-25 | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1679639A true CN1679639A (en) | 2005-10-12 |
Family
ID=35066645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100106168A Pending CN1679639A (en) | 2005-01-25 | 2005-01-25 | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1679639A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308012C (en) * | 2005-11-02 | 2007-04-04 | 广州中医药大学第二附属医院 | Chinese medicine composition for treating cerebral hemorrhage and its prepn |
| CN103263453A (en) * | 2013-03-14 | 2013-08-28 | 周苏秦 | Traditional Chinese medicine preparation for treatment of hyperlipidemia, hyperglycemia, high blood viscosity and hypertension and preparation method thereof |
| CN104547020A (en) * | 2015-01-20 | 2015-04-29 | 周苏秦 | Chinese medicinal compound preparation for treating hyperglycemia |
| CN112494607A (en) * | 2020-12-09 | 2021-03-16 | 云南中医药大学 | Pharmaceutical composition for preventing and treating cerebral apoplexy and application thereof |
| CN115089628A (en) * | 2022-07-08 | 2022-09-23 | 北京康恩泰生物医药有限公司 | Traditional Chinese medicine granule for treating coronary heart disease |
-
2005
- 2005-01-25 CN CNA2005100106168A patent/CN1679639A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308012C (en) * | 2005-11-02 | 2007-04-04 | 广州中医药大学第二附属医院 | Chinese medicine composition for treating cerebral hemorrhage and its prepn |
| CN103263453A (en) * | 2013-03-14 | 2013-08-28 | 周苏秦 | Traditional Chinese medicine preparation for treatment of hyperlipidemia, hyperglycemia, high blood viscosity and hypertension and preparation method thereof |
| CN104547020A (en) * | 2015-01-20 | 2015-04-29 | 周苏秦 | Chinese medicinal compound preparation for treating hyperglycemia |
| CN112494607A (en) * | 2020-12-09 | 2021-03-16 | 云南中医药大学 | Pharmaceutical composition for preventing and treating cerebral apoplexy and application thereof |
| CN115089628A (en) * | 2022-07-08 | 2022-09-23 | 北京康恩泰生物医药有限公司 | Traditional Chinese medicine granule for treating coronary heart disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1197481C (en) | Method for treatment of chronic venous insufficiencies using extract of red vine leaves | |
| CN101721507B (en) | Composition for relieving and treating fatty livers and preparation method thereof | |
| WO2016015391A1 (en) | Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor | |
| CN113041293A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| WO2023065376A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| CN1679639A (en) | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract | |
| CN104644901A (en) | Chinese medicinal preparation for long-term prevention and treatment of cardiovascular and cerebrovascular diseases at remission stage and preparation method of Chinese medicinal preparation | |
| CN1140279C (en) | Blood-cleaning pill | |
| CN1679725A (en) | Medicinal preparation of oral dropps with blood-activating Chinese medicine notogiseng and leech extract preparation | |
| CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| Sen et al. | A comprehensive review on Thankuni (Centella asiatica) as an herbal remedy in diabetes mellitus and wound healing | |
| CN111437301A (en) | Sophora flower cordyceps militaris preparation | |
| CN105727251B (en) | Pharmaceutical composition for treating fatty liver | |
| CN101066425A (en) | Chinese medicine prepn for treating ungual mycosis | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
| CN1248684C (en) | Chinese medicine powder for curing cardiovascular disease and preparing method thereof | |
| CN1250236C (en) | Application of levant cotton in medicine | |
| CN115487262A (en) | Composition for improving cardiovascular and cerebrovascular diseases and hypertension and preparation method thereof | |
| CN1265829C (en) | Healthy product for preventing and treating cardiovascular and cerebrovascular disease | |
| CN1762440A (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1943573A (en) | Use of vitamin C and arginine composition in anti-anoxic medicine and health product | |
| ANTON et al. | THE MEDICINAL RELEVANCE OF USING “OFFICINALE “AND “OFFICINALIS “AS PLANT SPECIES NAMES IN ROMANIAN FLORA | |
| CN1251720C (en) | Medicinal composition for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |